Description
Modafinil (Provigil, Modalert) is a eugeroic, a wakefulness-promoting agent. Pharmacologically it is explicitly not part of the classic stimulant class. Clinically it is approved for excessive daytime sleepiness in narcolepsy, obstructive sleep apnea and shift work sleep disorder. The difference from amphetamine derivatives is not a marketing detail - it shows up across the entire effect and side effect profile.
The mechanism is still not fully resolved. What is established is inhibition of the dopamine transporter (DAT), which raises extracellular dopamine. A 2009 PET study by Volkow and colleagues showed in humans that 200mg and 400mg modafinil substantially occupy striatal dopamine transporters and increase dopamine in the nucleus accumbens. Unlike amphetamines, however, modafinil does not actively release dopamine from vesicles - it only blocks reuptake. On top of that come indirect effects on the orexinergic and histaminergic systems of the hypothalamus, exactly the circuits that govern the sleep-wake cycle. That explains why the effect is usually described as “not tired” rather than “wired”.
Pharmacokinetically modafinil is well absorbed orally. Per the review by Robertson and Hellriegel, peak plasma concentration is reached 2 to 4 hours after dosing, steady state within 2 to 4 days. The elimination half-life is roughly 12 to 15 hours, which is the practically most important number of the whole substance: dosing in the afternoon pushes your sleep into the night. Elimination is mainly via amide hydrolysis in the liver, with less than 10 percent leaving the body unchanged. Relevant for interactions: modafinil induces CYP3A4 and inhibits CYP2C19.
The evidence on wakefulness is solid. In the randomized multicenter trial of the US Modafinil in Narcolepsy Study Group, 200mg and 400mg daily improved every objective and subjective sleepiness measure versus placebo. The effect held across 40 weeks of open-label continuation without tolerance developing. On the much-discussed cognitive improvement in rested healthy people the picture is considerably more sober: the meta-analysis by Roberts and colleagues (2020) found a statistically significant but small overall effect across 14 modafinil studies (SMD 0.12), essentially carried by memory updating. The authors state explicitly that the user perception of a strong cognitive enhancer is not supported by the data so far.
In a research context modafinil is therefore best classified as a wakefulness and vigilance compound, not an intelligence booster. It is of interest in work on shift schedules, shifted rhythms and attention across long waking phases. Abuse potential is low compared to amphetamines, but because of the demonstrated dopamine increase in the nucleus accumbens it is not zero, a point the Volkow paper makes explicitly.
You can order Modafinil as oral tablets with 200mg per tablet, 10 tablets per bottle. The 200mg+50mg size is a combination tablet: each tablet contains 200 mg modafinil and 50 mg armodafinil.
This information is for research and educational purposes only. No medical advice.
Risks & Safety
Modafinil is considered well tolerated in the registration trials, but it has two items in its profile that regularly get overlooked: rare but serious skin reactions and a real drug interaction with hormonal contraceptives. Both belong on the table before anyone engages with this substance.
Documented in clinical studies and registration data:
- Serious skin reactions: Registration documents record serious skin reactions up to and including Stevens-Johnson syndrome and toxic epidermal necrolysis. They are very rare, mostly occur within the first one to five weeks and are potentially life-threatening. Practical consequence: any new rash, any blistering and any involvement of mouth, eyes or mucous membranes is a reason to stop and a case for medical assessment, not something you “keep an eye on”.
- Interaction with hormonal contraceptives: Modafinil induces CYP3A4/5. In the controlled study by Robertson and colleagues (2002), exposure to ethinyl estradiol measurably decreased under 200mg to 400mg over four weeks. Prescribing information therefore flags reduced reliability of hormonal contraception during use and for about a month afterwards. This is the single most overlooked point with this substance.
- Further CYP interactions: Via CYP3A4 induction, substrates with high first-pass metabolism are affected (in the study, triazolam exposure fell considerably more than that of ethinyl estradiol). Modafinil additionally inhibits CYP2C19, which concerns substances such as diazepam, omeprazole, propranolol or phenytoin.
- Sleep displacement from the long half-life: At 12 to 15 hours, one dose taken late in the morning reaches far into the night. Late dosing reliably produces trouble falling asleep, shortened sleep and a following day where the sleep debt is merely masked rather than repaid.
- Headache as the most common effect: In the narcolepsy trials headache was by far the most frequent adverse event, dose-dependent and mostly mild to moderate. Nausea, nervousness, reduced appetite and dry mouth are also documented.
- Circulation: Mild increases in blood pressure and heart rate are described. Combined with other sympathomimetic substances these effects add up.
- Abuse and dependence potential: Lower than with amphetamines, but present. The Volkow paper explicitly derives from the dopamine increase in the nucleus accumbens that abuse potential in vulnerable groups cannot be ruled out. In the narcolepsy trials, discontinuation produced no amphetamine-type withdrawal symptoms - sleepiness simply returned to baseline.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Clinical pharmacokinetic profile of modafinil - Clinical Pharmacokinetics 2003, Robertson & Hellriegel: pharmacokinetic review with a 12-15 hour half-life, Tmax of 2-4 hours and the CYP interaction profile.
- Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications - JAMA 2009, Volkow et al: PET study showing dopamine transporter blockade and a dopamine increase in the nucleus accumbens after 200mg and 400mg in humans.
- Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy - Annals of Neurology 1998, US Modafinil in Narcolepsy Multicenter Study Group: 283 participants, 200mg and 400mg daily improved all sleepiness measures, effect stable across 40 weeks without tolerance.
- How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses - European Neuropsychopharmacology 2020, Roberts et al: meta-analysis across 14 modafinil studies with a small overall effect (SMD 0.12), carried by memory updating.
- Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers - Clinical Pharmacology & Therapeutics 2002, Robertson et al: controlled study in 41 women documenting CYP3A4/5 induction and reduced ethinyl estradiol exposure.
